Gubra announced today that members of the company’s leadership team will participate in upcoming investor conferences:
- Jefferies 2026 Global Healthcare Conference in London on November 16-19, 2026
- ABG Sundal Collier Nordic Opportunities Seminar in London on November 17-19, 2026
Contact at Gubra
Investors and Media: Adam Lange ([email protected], +45 6646 1589)
About Gubra
Gubra is a clinical-stage bioscience company founded in Denmark in 2008 and listed on Nasdaq Copenhagen. Building on deep expertise in peptide science, translational research, and advanced preclinical models, Gubra combines its AI-driven, disease-agnostic peptide drug discovery platform, streaMLine™, with specialized preclinical research capabilities. The company’s activities are organized into three distinct yet complementary business units: Gubra Biotech, the value driver, focused on discovering and advancing differentiated therapeutics; Gubra CRO, the value enabler, providing specialized preclinical research services; and Gubra Ventures, the value accelerator, focused on advancing selected external innovation through asset-centric ventures that leverage Gubra’s scientific capabilities and shared infrastructure. Gubra has approximately 300 employees and reported revenue of DKK 2.6 billion (USD ~400 million) in 2025.
For more information, visit www.gubra.dk.
